Evidence map›Paper›PMID 27001073›Full record

Observational studyBMC urology2016

Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy.

Shimpei Yamashita, Yasuo Kohjimoto, Takashi Iguchi, Hiroyuki Koike, Hiroki Kusumoto, Akinori Iba, Kazuro Kikkawa, Yoshiki Kodama, Nagahide Matsumura, Isao Hara

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in BMC urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Shimpei YamashitaDepartment of Urology, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-0012, Japan. keito608@wakayama-med.ac.jp.
Yasuo KohjimotoDepartment of Urology, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-0012, Japan.
Takashi IguchiDepartment of Urology, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-0012, Japan.
Hiroyuki KoikeDepartment of Urology, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-0012, Japan.
Hiroki KusumotoDepartment of Urology, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-0012, Japan.
Akinori IbaDepartment of Urology, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-0012, Japan.
Kazuro KikkawaDepartment of Urology, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-0012, Japan.
Yoshiki KodamaDepartment of Urology, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-0012, Japan.
Nagahide MatsumuraDepartment of Urology, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-0012, Japan.
Isao HaraDepartment of Urology, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-0012, Japan.
Wakayama Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWhile novel drugs have been developed, docetaxel remains one of the standard initial systemic therapies for castration-resistant prostate cancer (CRPC) patients. Despite the excellent anti-tumor effect of docetaxel, its severe adverse effects sometimes distress patients. Therefore, it would be very helpful to predict the efficacy of docetaxel before treatment. The aims of this study were to evaluate the potential value of patient characteristics in predicting overall survival (OS) and to develop a risk classification for CRPC patients treated with docetaxel-based chemotherapy.

methodsThis study included 79 patients with CRPC treated with docetaxel. The variables, including patient characteristics at diagnosis and at the start of chemotherapy, were retrospectively collected. Prognostic factors predicting OS were analyzed using the Cox proportional hazard model. Risk stratification for overall survival was determined based on the results of multivariate analysis.

resultsPSA response ≥50 % was observed in 55 (69.6 %) of all patients, and the median OS was 22.5 months. The multivariate analysis showed that age, serum PSA level at the start of chemotherapy, and Hb were independent prognostic factors for OS. In addition, ECOG performance status (PS) and the CRP-to-albumin ratio were not significant but were considered possible predictors for OS. Risk stratification according to the number of these risk factors could effectively stratify CRPC patients treated with docetaxel in terms of OS.

conclusionsAge, serum PSA level at the start of chemotherapy, and Hb were identified as independent prognostic factors of OS. ECOG PS and the CRP-to-albumin ratio were not significant, but were considered possible predictors for OS in Japanese CRPC patients treated with docetaxel. Risk stratification based on these factors could be helpful for estimating overall survival.

Indexed as

AdenocarcinomaAgedAged, 80 and overAge FactorsAntineoplastic AgentsBone Density Conservation AgentsBone NeoplasmsC-Reactive ProteinDiphosphonatesDocetaxelHumansKallikreinsKaplan-Meier EstimateLiver NeoplasmsLung NeoplasmsMaleAntineoplastic AgentsBone Density Conservation AgentsC-Reactive ProteinDiphosphonatesDocetaxelKallikreinsKLK3 protein, humanProstate-Specific AntigenSerum AlbuminTaxoidsCastration-resistant prostate cancerDocetaxelPrognostic factor

Identifiers

PMID27001073
PMCPMC4802623
OpenAlexW2303305587

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.